Ratio Therapeutics

This Thanksgiving, we want to express our deepest gratitude to our incredible team at Ratio and honor the hard work, dedication, and unwavering commitment to advancing cancer therapies that fuels this company. To our researchers, scientists, clinicians, and everyone behind the scenes—thank you for your passion and perseverance. We couldn’t do it without you. Wishing our team, partners, patients, and supporters a joyful and restful Thanksgiving.

Early detection is key in the fight against pancreatic cancer. Although it’s one of the toughest cancers to diagnose, being aware of the risk factors and symptoms can make all the difference. ?? Risk Factors Include: ? Family history of pancreatic cancer ? Chronic pancreatitis ? Diabetes ? Smoking and obesity ?? Symptoms to Watch For: ? Unexplained weight loss ? Persistent abdominal or back pain ? Yellowing of the skin and eyes (jaundice) ? Loss of appetite or digestive issues The Pancreatic Cancer Action Network is an excellent resource for learning more about pancreatic cancer, ongoing clinical trials, patient and caretaker support groups, and fundraising events to support research and advocacy. Ratio is proud to participate every year in the annual PanCAN Purple Stride Walk that occurs to fundraise for this important organization. If you or a loved one are at risk, speak with your healthcare provider about screening options. Early detection saves lives. #PancreaticCancerAwareness #EarlyDetectionSavesLives #KnowTheSigns #ScreeningMatters

Ratio CEO Dr. Jack Hoppin recently spoke with Kyle LaHucik of Endpoints News about Ratio’s collaboration agreement with Novartis, why he is so excited to partner with the Novartis team, and Ratio’s plans for 2025. ? The collaboration leverages Ratio’s radioligand therapy expertise and technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. ? Read here for additional insights into this deal: https://lnkd.in/d-vRK_vK ? #radiotherapeutics #biopharma #news

Today, Ratio is pleased to announce it entered into an exclusive worldwide license and collaboration agreement with Novartis. The collaboration leverages Ratio’s radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Learn more: https://lnkd.in/epx9g954 #radiopharmaceuticals #biotech #innovation #news

A recent report shows that the global #radiopharmaceutical market is on track to reach $26.5 billion by 2031. At Ratio, we're at the forefront of this growing field, developing therapies with life-changing potential. Read this reporting from Pharmaceutical Executive to discover why targeted radiopharmaceuticals are the future of oncology #investment: https://lnkd.in/e67-a6tb

November is #PancreaticCancerAwarenessMonth. This month, we stand in solidarity with patients, survivors, and their families in the fight against pancreatic cancer. At Ratio, our commitment goes beyond research—our employees have proudly supported Pancreatic Cancer Action Network through fundraising efforts, working together toward a future with better treatment options. Join us this month as we continue to raise awareness and support for those impacted. #radiopharmaceuticals

Radiopharmaceuticals are emerging as a powerful avenue for treating cancer. In this interview, Dr Jack Hoppin and Dr John Babich, Ratio Therapeutics, talk specifically how the therapy can combine with immuno-oncology to enhance activity and efficacy, for patient benefit. "You have the opportunity to not only reduce tumor burden and control tumor growth, but also stimulate inflammation locally on every site that the radioactivity lands on." Read the full interview here: https://lnkd.in/e7iG9WHX #IO360Summit #immunooncology #radiopharmaceuticals

#ICYMI – BioPharma Dive recently featured Ratio in this article from Michael Gibney about today’s radiopharma boom. Our CEO Jack Hoppin discusses why pharma has taken a renewed interest in #radiopharmaceuticals and why smaller companies are at the center of innovation for this field. Full article: https://lnkd.in/ernYtMdz

Next week, Ratio’s CSO, Dr. John Babich will participate in a virtual roundtable to discuss FAP-targeted PET imaging and theranostics. Hosted by Endpoints News , the webinar will take place on November 7, 2024 at 11 am ET. Tune in to learn how FAP-targeted PET introduces a new dimension in tumor evaluation, applicable to a broad range of cancers. Register now: https://lnkd.in/ea5kDvwg #radiopharmaceuticals #theranostics

Ratio is proud to be recognized as an honoree in this year’s BostInno Fire Awards. We’ve had tremendous growth in the past two years with a $50 million Series B funding round in January, bringing total raised funds to $90 million since 2022. This year also marked the first anniversary of our new 19,000-square-foot headquarters in Boston's Seaport District. Thank you BostInno for recognizing our successes as an early-stage biotech company in Boston. See the full list of #INNOFIRE honorees: https://lnkd.in/eCw7utud